IDEXX Laboratories, Inc. $IDXX Shares Purchased by Sax Wealth Advisors LLC

Sax Wealth Advisors LLC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,528 shares of the company’s stock after purchasing an additional 158 shares during the period. Sax Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $820,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. MorganRosel Wealth Management LLC acquired a new stake in IDEXX Laboratories during the first quarter worth about $26,000. Opal Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of IDEXX Laboratories by 55.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after acquiring an additional 30 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter valued at about $36,000. Finally, WPG Advisers LLC acquired a new stake in shares of IDEXX Laboratories during the first quarter valued at about $37,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price target on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a research report on Friday, August 15th. BTIG Research lifted their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Finally, Stifel Nicolaus set a $640.00 price target on shares of IDEXX Laboratories in a research report on Monday, August 4th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $656.50.

IDEXX Laboratories Stock Up 0.4%

Shares of IDEXX Laboratories stock opened at $629.91 on Thursday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12. The company has a 50 day moving average of $637.99 and a 200 day moving average of $539.07. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $50.40 billion, a P/E ratio of 52.45, a P/E/G ratio of 4.06 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the firm earned $2.44 earnings per share. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Nimrata Hunt sold 7,143 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the transaction, the executive vice president owned 18,007 shares in the company, valued at $11,352,153.01. The trade was a 28.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the sale, the chief executive officer owned 83,311 shares of the company’s stock, valued at $52,650,885.78. This represents a 25.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock valued at $34,293,468 over the last ninety days. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.